Copyright © 2001 by the European Society of Cardiology.
Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II
a TIMI Study Group, Cardiovascular Division, Brigham & Women's Hospital and Harvard Medical School, Boston, MA
b Division of Cardiovascular Medicine, Queen's Medical Centre, Nottingham, U.K.
c Fundacion Favaloro, Buenos Aires, Argentina
d Nottingham Clinical Research Group, Nottingham, U.K.
revised December 21, 2000; accepted January 2, 2001
Abstract
Aims We examined the geographic variations in InTIME-II, a randomized double-blind trial comparing alteplase with lanoteplase for myocardial infarction.
Methods and Results We compared baseline characteristics, management, and outcomes in four regions (Western Europe, Eastern Europe, North America, and Latin America) and in countries with historically different management approaches (Germany vs the U.K., the U.S. vs Canada). Thirty-day mortality in Western Europe, Eastern Europe, North America and Latin America was 6·7%, 7·3%, 5·7%, 10·1%, P<0·0001. Adjusted mortality for Europe was intermediate between North America and Latin America (odds ratios (OR) [95% confidence intervals (CI)] compared to Western Europe: North America 0·84 [0·67–1·0], Eastern Europe 1·2 [1·0–1·4], and Latin America 1·8 [1·3–2·7]). Revascularization rates varied 10-fold but did not explain regional mortality differences. Germany and the U.K. had similar adjusted 1-year mortality (OR for the U.K. 1·16 [0·92–1·5]), although invasive procedures were four- to 10-fold more common in Germany. Similarly the U.S. and Canada had equal adjusted 1-year mortality (OR for Canada 0·85 [0·61–1·17]) despite three-fold higher use of invasive procedures in the U.S.
Conclusions Significant geographic variations in practice and adjusted mortality following fibrinolysis persist despite recent guidelines. These findings have important implications in the design and interpretation of international studies, identify under- and over-utilized therapies, and support further study of treatments with marked worldwide variations.
Key Words: Myocardial infarction, fibrinolysis, geographic variation, management, outcomes
f1 These authors contributed equally to the manuscript.
f2 Correspondence: Dr Robert P. Giugliano, TIMI Study Office, 333 Longwood Avenue, Suite 402, Boston, MA 02115, U.S.A.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J.J. Edmond, J.K. French, P.E.G. Aylward, C.K. Wong, R.A.H. Stewart, B.F. Williams, C.G. De Pasquale, R.L. O'Connell, K. Van den Berg, F.J. Van de Werf, et al. Variations in the use of emergency PCI for the treatment of re-infarction following intravenous fibrinolytic therapy: impact on outcomes in HERO-2 Eur. Heart J., June 2, 2007; 28(12): 1418 - 1424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kaul, W.-C. Chang, A. M. Lincoff, P. Aylward, A. Betriu, C. Bode, R. M. Califf, E. M. Ohman, V. Guetta, P. G. Steg, et al. Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial Eur. Heart J., May 2, 2006; 27(10): 1198 - 1206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-C. Chang, W. K Midodzi, C. M Westerhout, E. Boersma, J. Cooper, E. S Barnathan, M. L Simoons, L. Wallentin, E M. Ohman, P. W Armstrong, et al. Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis J Epidemiol Community Health, May 1, 2005; 59(5): 427 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kashani, R. P. Giugliano, E. M. Antman, D. A. Morrow, C. M. Gibson, S. A. Murphy, and E. Braunwald Severity of heart failure, treatments, and outcomes after fibrinolysis in patients with ST-elevation myocardial infarction Eur. Heart J., October 1, 2004; 25(19): 1702 - 1710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Morrow, E. M. Antman, S. A. Murphy, S. F. Assmann, R. P. Giugliano, C. P. Cannon, C. Michael Gibson, C. H. McCabe, H. V. Barron, F. Van de Werf, et al. The Risk Score Profile: a novel approach to characterising the risk of populations enrolled in clinical studies Eur. Heart J., July 1, 2004; 25(13): 1139 - 1145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gupta, W.-C. Chang, F. Van de Werf, C. B. Granger, W. Midodzi, G. Barbash, K. Pehrson, A. Oto, P. Toutouzas, P. Jansky, et al. International differences in in-hospital revascularization and outcomes following acute myocardial infarction: A multilevel analysis of patients in ASSENT-2 Eur. Heart J., September 2, 2003; 24(18): 1640 - 1650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gabriel Steg, B. Iung, L. J Feldman, A. P Maggioni, U. Keil, J. Deckers, D. Cokkinos, K. A.A Fox, and for the ENACT investigators Determinants of use and outcomes of invasive coronary procedures in acute coronary syndromes: results from ENACT Eur. Heart J., April 1, 2003; 24(7): 613 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R M Martin, H Hemingway, D Gunnell, K R Karsch, A Baumbach, and S Frankel Population need for coronary revascularisation: are national targets for England credible? Heart, December 1, 2002; 88(6): 627 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.S. Alpert Acute coronary syndromes observed from an international perspective Eur. Heart J., August 1, 2002; 23(15): 1139 - 1140. [Full Text] [PDF]
|
|
|
|
|
|
T. O. Cheng Importance of ethnic differences in affecting the outcomes of international trials Eur. Heart J., February 1, 2002; 23(3): 256 - 256. [Full Text] [PDF]
|
|
|
|
|
|
J Llevadot, R.P Giugliano, E.M Antman, R.G Wilcox, E.P Gurfinkel, T Henry, C.H McCabe, A Charlesworth, S Thompson, J.C Nicolau, et al. Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction Eur. Heart J., November 2, 2001; 22(22): 2104 - 2115. [Abstract] [PDF]
|
|
|
|
|
|
F. Van de Werf Why is there so much geographic variation in clinical outcome in international trials of fibrinolytic therapy? Eur. Heart J., September 2, 2001; 22(18): 1631 - 1632. [PDF]
|
|